Mutant-type uricase, PEG modified mutant-type uricase, and application thereof
AssigneeShanghai Institute of Biological Products Co., Ltd.
InventorsYun Jiang, Linqiu Huang, Jueren Lou
Life of this patent
Estimating the term…
Abstract
A mutant-type uricase, PEG modified mutant-type uricase, and application thereof. The mutant-type uricase has a cysteine residue introduced by recombination, the cysteine residue is located at an inactive region of the uricase, and one or more PEGs are coupled to the mutant-type uricase. The resulting PEGylated mutant-type uricase has characteristics of a half-life extension, product uniformity, and stable enzyme activity. Therefore, the present invention has a wide future application range.
Claims9
A mutant uricase, which has a recombinantly introduced cysteine residue, and the cysteine residue is located in an inactive region of the uricase;
- the inactive region is a region of uricase selected from a group consisting of:
- (a) positions 148±1, 202±1, 228±1, 291±1 of uricase;
- and
- (b) after the C-terminus of uricase;
- wherein the amino acid position is based on the uricase sequence as shown in SEQ ID NO.:
- 1, and wherein the introduction of the recombinantly introduced cysteine residue includes substitution, insertion, and/or addition.
Dependencies are inferred from the claim text.